Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.

Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.

Gastric cancer is the second common cause of cancer related death worldwide and lacks highly effective treatment for advanced disease. Nab-paclitaxel is a novel microtubule-inhibitory cytotoxic agent that has not been tested in gastric cancer as of yet. In this study, human gastric cancer cell lines...

Full description

Bibliographic Details
Main Authors:	Changhua Zhang, Niranjan Awasthi, Margaret A Schwarz, Stefan Hinz, Roderich E Schwarz
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3584019?pdf=render

Similar Items

Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma
by: Md Sazzad Hassan, et al.
Published: (2018-04-01)

Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
by: Niranjan Awasthi, et al.
Published: (2012-01-01)

Comparison of Peripheral Neuropathy Induced by Standard and Nanoparticle Albumin–Bound Paclitaxel in Rats
by: Yuji Yamashita, et al.
Published: (2011-01-01)

Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (-paclitaxel) in metastatic breast cancer: which benefit for which patients?
by: Raffaella Palumbo, et al.
Published: (2016-05-01)

Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer
by: Mashiro Okunaka, et al.
Published: (2020-11-01)

Albumin-bound paclitaxel in the treatment of metastatic breast cancer
by: E V Artamonova
Published: (2017-01-01)

Exceptional Response to Nanoparticle Albumin-Bound Paclitaxel and Gemcitabine in a Patient with a Refractory Adenocarcinoma of the Ampulla of Vater
by: Markus Kapp, et al.
Published: (2016-01-01)

Nanoparticle Albumin-Bound Paclitaxel- and/or Gemcitabine-Induced Scleroderma Accompanied by Acanthosis Nigricans-Like Skin Changes
by: Sei-ichiro Motegi, et al.
Published: (2019-10-01)

Nanoparticle Albumin-Bound-Paclitaxel in the Treatment of Metastatic Urethral Adenocarcinoma: The Significance of Molecular Profiling and Targeted Therapy
by: Yasmin M. Abaza, et al.
Published: (2014-01-01)

Successful treatment with carboplatin and nanoparticle albumin-bound paclitaxel in a patient with pulmonary spindle cell carcinoma
by: Takahiro Tsuji, et al.
Published: (2015-01-01)

Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma
by: Zhichao Tian, et al.
Published: (2020-07-01)

Gelatin Methacryloyl Hydrogels Control the Localized Delivery of Albumin-Bound Paclitaxel
by: Margaux Vigata, et al.
Published: (2020-02-01)

Albumin-bound paclitaxel in solid tumors: clinical development and future directions
by: Kundranda MN, et al.
Published: (2015-07-01)

Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer
by: Francesco Di Costanzo, et al.
Published: (2009-07-01)

Pure redox-sensitive paclitaxel–maleimide prodrug nanoparticles: Endogenous albumin-induced size switching and improved antitumor efficiency
by: Xinyu Lou, et al.
Published: (2021-07-01)

Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Elderly Patients with Metastatic Breast Cancer: A Meta-Analysis
by: Xin Li, et al.
Published: (2019-10-01)

Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma
by: Shi Y, et al.
Published: (2013-05-01)

Preparation and antitumor activities of chitosan-silica-paclitaxel nanoparticles
by: 楊翔茵
Published: (2008)

Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer
by: Schwarz Margaret A, et al.
Published: (2011-01-01)

Clinical effect of albumin-bound paclitaxel in treatment of advanced primary liver cancer
by: JI Shiyu, et al.
Published: (2016-10-01)

Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients
by: Qingmei Li, et al.
Published: (2018-11-01)

Clinical Research on Albumin-bound Paclitaxel-based Therapy in Advanced Lung Cancer
by: Xu LI, et al.
Published: (2017-06-01)

Clinical effect of nanoparticle albumin-bound paclitaxel combined with gemcitabine in treatment of advanced pancreatic cancer: A meta-analysis
by: WANG Yun, et al.
Published: (2019-05-01)

Cell proliferation and migration are modulated by Cdk-1-phosphorylated endothelial-monocyte activating polypeptide II.
by: Margaret A Schwarz, et al.
Published: (2012-01-01)

Ultra-widefield angiographic imaging of albumin-bound paclitaxel-induced cystoid macular edema
by: Junhyuck Lee, et al.
Published: (2019-01-01)

Research Progresses of Albumin-bound Paclitaxel in the Treatment of Non-small Cell Lung Cancer
by: Peng LI, et al.
Published: (2010-07-01)

Nanoparticle albumin‐bound paclitaxel in elder patients with advanced squamous non‐small‐cell lung cancer: A retrospective study
by: Yang Liu, et al.
Published: (2020-02-01)

Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients
by: Fabi A, et al.
Published: (2015-11-01)

Sub-Tenon Injections of Triamcinolone Acetonide Had Limited Effect on Cystoid Macular Edema Secondary to Nanoparticle Albumin-Bound-Paclitaxel (Abraxane)
by: Naoki Matsuoka, et al.
Published: (2015-01-01)

Albumin-bound formulation of paclitaxel (Abraxane&reg; ABI-007) in the treatment of breast cancer
by: Evelina Miele, et al.
Published: (2009-04-01)

Macrophage Polarization Contributes to the Anti-Tumoral Efficacy of Mesoporous Nanovectors Loaded with Albumin-Bound Paclitaxel
by: Fransisca Leonard, et al.
Published: (2017-06-01)

Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A prospective self-controlled trial
by: Yuko Kanbayashi, et al.
Published: (2020-02-01)

Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System
by: Misa Naganuma, et al.
Published: (2019-03-01)

Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer
by: Yuki Nakatani, et al.
Published: (2017-08-01)

Paclitaxel-Loaded Macrophage Membrane Camouflaged Albumin Nanoparticles for Targeted Cancer Therapy
by: Cao X, et al.
Published: (2020-03-01)

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
by: Palumbo R, et al.
Published: (2015-04-01)

Weekly nanoparticle albumin bound-paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma
by: Wang HY, et al.
Published: (2016-09-01)

Preparation, Characterization, and in Vitro/in Vivo Evaluation of Paclitaxel-Bound Albumin-Encapsulated Liposomes for the Treatment of Pancreatic Cancer
by: Yuko Okamoto, et al.
Published: (2019-05-01)

SPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer
by: Komiya K, et al.
Published: (2016-10-01)

Combination Therapy of Albumin-Bound Paclitaxel and Carboplatin as First Line Therapy in a Patient with Ovarian Cancer
by: K. N Srinivasan, et al.
Published: (2014-01-01)

Cannot write session to /tmp/vufind_sessions/sess_8udr4neom7f3btrih5v5f11mpc